



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

The comparison of clinical characteristics between imported and native cases of COVID-19 in China

Ting Cheng, MD, MPH, Yong Li, MD, Lin Wang, RN, Jingya Zhao, MD, PhD, Li Liu, MD, PhD, Hongzhou Lu, MD, PhD, Qijian Cheng, MD, PhD



PII: S1687-8507(22)07157-6

DOI: <https://doi.org/10.1016/j.jrras.2022.04.007>

Reference: JRRAS 400

To appear in: *Journal of Radiation Research and Applied Sciences*

Received Date: 22 December 2021

Revised Date: 2 April 2022

Accepted Date: 25 April 2022

Please cite this article as: Cheng T., Li Y., Wang L., Zhao J., Liu L., Lu H. & Cheng Q., The comparison of clinical characteristics between imported and native cases of COVID-19 in China, *Journal of Radiation Research and Applied Sciences*, <https://doi.org/10.1016/j.jrras.2022.04.007>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Ting Cheng, MD, MPH^{#1,2,3}; Yong Li, MD^{#1,2,3}; Lin Wang, RN^{#4}; Jingya Zhao, MD, PhD^{1,3}, Li Liu, MD, PhD^{*5}; Hongzhou Lu, MD, PhD^{*5,6}; Qijian Cheng, MD, PhD^{*1,2,3}

The comparison of clinical characteristics between imported and native cases of COVID-19 in China

Running Title: Imported COVID-19 in China

¹Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

²Department of Respiratory Medicine, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine, Shanghai, China

³Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

⁴Department of Nursing, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

⁵Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

⁶Department of Infectious Disease, HuaShan Hospital Affiliated to Fudan University, Shanghai, China

#Co-first author

***Co-corresponding authors**

Correspondence:

(Main) Dr. Li Liu, No. 2901 Caolang Road, Shanghai, 201508, China; liliu2021@yeah.net; Tel:
86-021-37990333

Dr. Hongzhou Lu, No. 2901 Caolang Road, Shanghai, 201508, China; luhongzhou@fudan.edu.cn

Dr. QiJian Cheng, No. 999 Xiwang Road, Shanghai, 201800, China; chengqijian@aliyun.com

Journal Pre-proof

Abstract

The study aimed to determine the trends in the manifestations and severity over the epidemic course of imported COVID-19 cases, with comparison to native cases. The clinical characteristics of imported and native Chinese COVID-19 cases included in the study were assessed and compared. The association was analyzed using Mann-Whitney U test for categorical variables, Kruskal-Wallis H test for continuous variables, and Spearman's correlation test for disease severity. A total of 247 imported patients were enrolled, with an average age of 29 years, and 41.3% were female. The imported patients were younger than the native patients (29 vs 47 years) and included a lower proportion of fever (44.1%), chills (5.3%), fatigue (10.1%), leukopenia (14.6%), lymphopenia (39.3%), elevated C-reactive protein (CRP) (7.3%), elevated D-dimer (16.3%), and pneumonia (65.6%). Among patients with moderate severity, imported cases had a lower proportion of fever (44.2%), dyspnea (8.3%), and increased CRP (7.7%) than native cases. COVID-19 infection was less severe in imported cases than that in native cases, reflected by fewer clinical symptoms, fewer comorbidities, and lower overall severity.

Keywords: COVID-19; clinical features; imported case; native case

1. Introduction

In December 2019, a series of pneumonia cases of unknown cause was discovered in Wuhan, Hubei, China (Huang et al, 2020). The clinical and imaging presentation markedly resembled viral pneumonia, including fever, fatigue, cough, dyspnea, normal or decreased white blood cell count, and bilateral ground-glass opacity and consolidation on chest computed tomography (CT). However, the disease could cause severe complications, including acute respiratory distress syndrome, and considerable mortality, even in patients who were previously in a health condition. The causative pathogen was identified as a novel coronavirus (Zhu et al, 2020), which were first named as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) by the International Committee on Taxonomy of Viruses, and then formally named as “corona virus disease 2019 (COVID-19)” by the World Health Organization (WHO) (Jie-Ming et al, 2020).

The first wave of infection was mainly linked to the Huanan Seafood Market in Wuhan Hubei Province, China in late December 2019. Confirmed of a human-to-human transmission (Li et al, 2020), COVID-19 has formally declared a global pandemic on March 11, 2020 (Jie-Ming et al, 2020). By October 19, 2020, a total of 40 million cases were confirmed with COVID-19, including over 1 million deaths in over 200 countries, reported by WHO (World Health Organization). While, the incidence and mortality rates were continuously increasing.

With rapid response and aggressive public health interventions, the COVID-19 epidemic was largely contained in China (The 2020), reflected by the reduced number of newly confirmed native cases. Accordingly, a large number of Chinese individuals living abroad returned to China to avoid SARS-COV-2 infection. However, some of them had already been infected before getting back (Chen et al, 2020). Although these imported cases posed new challenges for both China (Chen et al, 2020) and other countries as the global pandemic worsen, little was known about the

characteristics of imported COVID-19 cases. This study aimed to determine the trends in the manifestations and severity over the epidemic course of imported COVID-19 cases, with comparison to native cases.

2. Methods

2.1 Study design and participants

This study was approved by the Ethics Committee of Shanghai Public Health Clinical Center (SPHCC), and informed consent was obtained from all patients.

This was an ecological study of 247 Chinese patients who returned to Shanghai, China from 21 countries between March 6 and April 30, 2020, and have been diagnosed with COVID-19. Only patients aged ≥ 15 years were enrolled. Patients were screened and diagnosed according to national guidelines and local protocols³ (Figure 1-2). All patients were followed-up until May 30, 2020. In addition, we included 265 native Chinese patients from a Shanghai cohort and 1099 patients from a nationwide cohort. The Shanghai cohort comprised patients admitted to SPHCC, who were diagnosed with COVID-19 before February 7, 2020, and followed up till February 11, 2020 (Lu et al, 2020). The nationwide cohort included patients across China through December 11, 2019, to January 29, 2020, who were followed up till January 31, 2020 (Guan et al, 2020).

2.2 Laboratory confirmation of SARS-CoV-2 infection

SARS-CoV-2 infection was confirmed via viral nucleic acid testing performed by the district Centre for Disease Control and Prevention (CDC) or authenticated testing company and confirmed by the Shanghai CDC, according to the recommendation by the National Institute for Viral Disease Control and Prevention, China.

2.3 COVID-19 Clinical Severity Classification

Disease severity was classified as (1) mild: minor symptoms with no pneumonia manifestations on lung imaging examination; (2) moderate: fever and respiratory symptoms with pneumonia manifestations on CT images, but with no dyspnea or other complications; (3) severe: shortness of breath (respiratory rate [RR] ≥ 30 beats/min); resting state mean oxygen saturation $\leq 93\%$; partial pressure of arterial oxygen/fraction of inspired oxygen ≤ 300 mmHg; or pulmonary imaging showed that lesions had progressed by $> 50\%$ within 24–48-h period), and (4) critical: any one of the following conditions occurred, including respiratory failure requiring mechanical ventilation, shock, or multi-organ failure requiring intensive care unit (ICU) monitoring and treatment (Jie-Ming et al, 2020; Feng et al, 2020).

2.4 Data collection

Epidemiological and demographic data, underlying comorbidities, clinical symptoms and signs throughout the disease course, CT imaging, and laboratory findings at admission were extracted from electronic medical records. Laboratory assessments consisted of complete blood count, liver and renal function tests, electrolytes, arterial and venous lactate, C-reactive protein (CRP), procalcitonin, coagulation test, lactate dehydrogenase, and creatine kinase.

2.5 Statistical analysis

The presence or absence of symptoms and comorbidities, and most laboratory test results classified as normal, higher, and lower, were coded as categorical variables. Body temperature and disease severity were coded as rank variables. The intervals between symptom onset and admission, and length of hospital stay (LOS) were coded as continuous variables.

Categorical and rank variables were expressed as frequencies (%), while continuous variables were expressed as the median (interquartile range, IQR). Between-group comparisons of the categorical variables were conducted using the χ^2 test or Fisher's exact test, while rank and

continuous variables were compared using the Mann-Whitney U test and Kruskal-Wallis H test. The association was analyzed using Mann-Whitney U test for categorical variables, Kruskal-Wallis H test for continuous variables, and Spearman's correlation test for disease severity. All statistical analyses were performed using SPSS version 25.0 (IBM Inc., Armonk, NY). A difference with $P < 0.05$ was regarded as statistically significant.

3. Results

3.1 Demographic and clinical characteristics

A total of 247 imported patients were enrolled, with an average age of 29 years, and 41.3% of whom were female. The most common country of origin was Russia ($n = 86$, 34.82%), followed by the United Kingdom (UK) ($n = 76$, 30.77%) and the United States of America (USA) ($n = 34$, 13.77%). The remaining 51 (20.65%) patients were from other countries. The patients from Russia were mainly businessmen, while the patients from USA and UK were mainly Chinese overseas students.

The baseline demographic characteristics of imported cases and two cohorts were shown in Table 1. The imported cases were significantly younger than the native cases (median [IQR]: 29 years [21–40 years] vs 47 years [35–58 years] (national cohort), $P < 0.001$). In addition, sex and age proportions were different among various countries of disease origins ($P = 0.022$ and $P < 0.001$, respectively). For comorbidities, imported cases had a significantly lower proportion of hypertension (5.3% vs 19.6% and 15.0%) and coronary heart disease (0% vs 5.3% and 2.5%) than native cases.

3.2 COVID-19 characteristics

Based on the most severe situation over the whole disease course, 84 (34.1%) patients were classified as mild, 156 (63.4%) were moderate, 5 (2.0%) were severe, and 1 (0.4%) was critical in

the imported cases, which were less severe than native cases ($P < 0.001$). Furthermore, the severity was also different among cases with different origins overall ($P = 0.004$). The cases from Russia were more severe than the cases from UK ($P < 0.001$).

The proportion of pneumonia was lower in imported cases, compared with native cases (65.6% vs 91.1% (national cohort), $P < 0.001$, Table 2). Compared with native cases, imported cases had a lower prevalence of fever (44.1% vs 90.9% (Shanghai cohort) and 88.7% (national cohort), both $P < 0.001$), chills (5.3% vs 11.5% (national cohort), $P < 0.001$), and fatigue (10.1% vs 25.3% (Shanghai cohort) and 38.1% (national cohort), both $P < 0.001$). While, imported cases had a higher prevalence of nasal congestion (15.8% vs 4.8% (national cohort), $P < 0.001$). Meanwhile, there was no significant between-group difference concerning the proportion of patients with cough, productive sputum, myalgia or arthralgia, dyspnea or chest tightness, and diarrhea. Ageusia or anosmia was identified in 9.7% of the imported cases.

There was a large disparity of clinical symptoms among cases with different country origins. The proportion of patients who had a diagnosis of pneumonia was different ($P = 0.006$), with a higher proportion in cases originating in Russia than those in UK ($P = 0.002$). In addition, the prevalence of chills and dyspnea/chest tightness differed among the cases originating from Russia were higher than those from UK ($P = 0.012$ and 0.003 , respectively). While, the highest body temperature and the prevalence of other symptoms had no significant difference by country of origin.

In patients with moderate severity, the most frequent symptom was cough (53.8%), followed by fever (44.2%), itchy throat (31.4%), and sputum production (26.9%). The proportion of patients with fever (44.2% vs 82.2%, $P < 0.001$), dyspnea (8.3 vs 14.9%, $P = 0.040$), and elevated CRP (7.7% vs 55.0%, $P < 0.001$) in moderate imported cases remained significantly lower than in

moderate native cases. There was no significant difference in the proportion of patients with the remaining clinical characteristics.

3.3 Laboratory and imaging characteristics

The laboratory and imaging findings were shown in Table 3. Compared with native cases, imported cases showed a lower prevalence of leukopenia (14.6% vs 33.7%, $P < 0.001$), lymphopenia (39.3% vs 83.2%, $P < 0.001$), thrombocytopenia (8.9% vs 36.2%, $P < 0.001$), elevated CRP (7.3% vs 60.7%, $P < 0.001$), elevated alanine aminotransferase (ALT) (15% vs 21.3%, $P = 0.034$), elevated aspartate aminotransferase (AST) (3.6% vs 22.2%, $P < 0.001$), renal insufficiency (0.0% vs 1.6%, $P = 0.045$), elevated creatine kinase (6.9% vs 13.7%, $P = 0.005$), elevated lactate dehydrogenase (8.5% vs 41.0%, $P < 0.001$), and elevated D-dimer (16.3% vs 46.4%, $P < 0.001$).

Abnormalities on chest CT on admission were detected in 56.7% of imported cases, which was lower than that in native cases (86.2%, $P < 0.001$). The proportion of patients with bilateral lung involvement was also significantly lower in imported cases (34.0% vs 77.4%, $P < 0.001$). The most common abnormal findings on CT were ground-glass opacities (38.1%), followed by patchy effusion or consolidation (25.9%) and interlobular septal thickening (23.1%) in imported cases, similar to native cases.

3.4 Association between baseline and clinical characteristics and disease severity

The results of baseline and clinical characteristics classified with disease severity were shown in Table 4, Supplementary Tables 1-2. There was a significant correlation between disease severity and age (Spearman's correlation $r = 0.386$, $P < 0.001$). Furthermore, disease severity was significantly associated with hypertension ($P = 0.002$), diabetes ($P < 0.001$), cough ($P < 0.001$), productive sputum ($P = 0.004$), leukopenia ($P = 0.026$), lymphocytopenia ($P < 0.001$),

hypoalbuminemia ($P < 0.001$), increased CRP ($P = 0.001$), increased ALT ($P = 0.018$), increased AST ($P = 0.002$), increased lactate dehydrogenase ($P < 0.001$), D-dimer ($P = 0.040$), and more lung lobes involved (in moderate to critical patients, $r = 0.160$, $P = 0.049$).

The comparison of clinical characteristics between asymptomatic patients and symptomatic patients was shown in Supplementary Table 3. Asymptomatic patients had a lower prevalence of bilateral lung involvement ($P = 0.042$), multiple lobar involvements ($P = 0.018$), and ground-glass opacities ($P = 0.014$). Meanwhile, there was no significant difference in age, sex, comorbidities and laboratory abnormalities between the asymptomatic and symptomatic patients.

4. Discussion

Our findings indicated that COVID-19 infection was less severe in imported cases than that in native cases, reflected by lower overall severity, a higher percentage of asymptomatic patients and lower number of patients with fever, pneumonia, leukopenia, lymphopenia, and elevated CRP, ALT, AST, creatine kinase, lactate dehydrogenase, and D-dimer.

In this study, three Chinese cohorts were involved in the comparison. Shanghai cohort reported by Lu et al. (Lu et al, 2020) was used as a reference for comparison because it involved native Chinese COVID-19 patients who were diagnosed, treated, and followed up by the same hospitals, using the same protocol. Meanwhile, the national cohort reported by Guan et al (Guan et al, 2020) was a complete and detailed case series report of native Chinese patients, with a relatively large sample size. In addition, another cohort reported by Feng et al (Feng et al, 2020) was used as a reference for comparison in patients with moderate severity.

Several factors might contribute to less severe manifestations in imported cases. First, the imported cases were younger and had fewer comorbidities, which were reported to have an influence on disease severity (Liu et al, 2020; Chen et al, 2020; Zhou et al, 2020). Second, in the

early stage of the epidemic, severe cases were more likely to be tested, diagnosed, and admitted, which might cause a selection bias (Weiss and Murdoch 2020). The evolution of the screening strategy might have helped the timely identification of more asymptomatic and mild patients. However, the native cases were also largely identified in a timely manner under Shanghai's active surveillance program, shown in the Shanghai cohort (Lu et al, 2020). In addition, the pathogenicity of the virus may be diminished after multigenerational transmission under selection pressure (Lei et al, 2020). For instance, the cases in Guangzhou were reported to have a less severity, compared with those in Wuhan (Lei et al, 2020). However, the evolution of the manifestations and severity of the disease over the course of the epidemic remains unknown. Further studies were warranted to confirm the findings.

A recent meta-analysis (Liu et al, 2020) showed a significantly higher incidence of cough, dyspnea, nasal congestion, and digestive symptoms in patients from North American, European, and Middle East countries than those from East and South-East Asian countries. While, there were no significant differences in the incidence of fever, lymphocytopenia, and thrombocytopenia by country of origin. Given the high incidence of the asymptomatic patients in West countries (Oran and Topol 2020), these manifestations of patients in West countries were consistent with the imported patients in the present study. This suggested that, in this epidemic, the incidence of various clinical symptoms might have a regional specificity regardless of ethnicity. In addition, it was reported that 55% of COVID-19 patients presented with anosmia or ageusia in a London population (Patel et al, 2020), which might be related to the damage of olfactory and taste receptors (Jasti et al, 2020). The incidence of ageusia or anosmia in COVID-19 patients in China was reported to be 32%, significantly lower than that in Germany and France (Qiu et al, 2020). While, only 9.8% of the imported cases presented with ageusia or anosmia in the present study. Patients

with ageusia or anosmia in the study had less severe disease, which was consistent with the previous findings (Haehner et al, 2020; Moein et al, 2020). Furthermore, liver involvement was a common occurrence in COVID-19 infection (Saviano et al, 2020). Recent studies showed that 41.6% and 66.9% of the 1,827 patients in the USA presented with elevated ALT and AST on admission (Hundt et al, 2020). However, only 27.3% (227/830) of the Chinese COVID-19 patients showed liver biochemistry abnormality on admission (Chen et al, 2020). A meta-analysis including former data also showed that the cases from West countries had a higher incidence of elevated ALT and AST than those from East countries (Liu et al, 2020). In the present study, the imported Chinese cases showed a lower prevalence of elevated ALT and AST than did the native Chinese cases, indicating that a low prevalence of liver injury may be related to the Chinese ethnicity.

Previous studies reported that patients with older age (Liu et al, 2020; Chen et al, 2020; Zhou et al, 2020), hypertension (Zhou et al, 2020), diabetes (Zhou et al, 2020), leukopenia (Guan et al, 2020; Feng et al, 2020), lymphocytopenia (Guan et al, 2020; Feng et al, 2020), hypoalbuminemia (Chen et al, 2020; Zhou et al, 2020), high CRP (Feng et al, 2020; Chen et al, 2020), high ALT and AST (Chen et al, 2020), high lactate dehydrogenase (Chen et al, 2020), and high D-dimer (Chen et al, 2020) levels had a more serious disease. Our findings on the association between certain clinical characteristics and disease severity were consistent with those in previous studies on native Chinese COVID-19 patients. However, previous studies on the association between incidence of fever and disease severity in native Chinese patients had inconsistent findings. Two studies found that fever was not a predicting factor for ICU admission and in-hospital death (Chen et al, 2020; Zhou et al, 2020). In contrast, another study reported a significantly higher proportion of patients with fever in severe patients (Feng et al, 2020). The proportion of patients with fever was higher in the more severely affected patients, but with no statistical significance in the present study.

In the present study, 11.7% of imported cases were asymptomatic throughout the course of their disease, which was markedly higher than that in native Chinese patients (1%) from the nationwide survey (Wu and McGoogan 2020). In the Diamond Princess cruise ship, approximately 17.9% of patients were asymptomatic (Mizumoto et al, 2020). In Italy, 6.7% of cases had no symptoms and 6.7% had few symptoms, based on a nationwide research (Livingston and Bucher 2020). However, it should be noted that asymptomatic patients could still be infectious (Bai et al, 2020). The laboratory and chest CT examination in this study suggested that pathophysiological changes occurred in asymptomatic patients, who also needed to be quarantined and undergo close observation.

Our study had some limitations. First, the sample size was relatively small. Second, native cases were identified from published data, and detailed individual information could not be obtained. Thus, it was difficult to minimize the influence of the confounding factors. Third, the laboratory findings were mainly classified as dichotomy or grade, which might reduce the sensitivity to find differences among COVID-19 patients. Fourth, information on virus generation and evolution were not available. Further studies are needed to evaluate the impact of different SARS-CoV-2 lineages, host (including ethnicity) and environmental factors on the disease manifestations and severity.

In summary, COVID-19 infection was less severe in imported cases than that in native cases, reflected by fewer clinical symptoms, fewer comorbidities, and lower overall severity.

List of abbreviations:

ALT: alanine aminotransferase

AST: aspartate aminotransferase

Conflict of Interest

The authors declare that they have no conflicts of interest.

Funding

This work was supported by Scientific Research Projects of the Shanghai Municipal Health Commission for youths (Project No. 20204Y0016), Shanghai Municipal Key Clinical Specialty (shslczdk02202), Shanghai Top-Priority Clinical Key Disciplines Construction Project (2017ZZ02014), Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases (20dz2261100) and Cultivation Project of Shanghai Major Infectious Disease Research Base (20dz2210500).

CDC: Centre for Disease Control and Prevention

COVID-19: coronavirus disease 2019

CRP: C-reactive protein

CT: computed tomography

ICU: intensive care unit

IQR: interquartile range

LOS: length of stay

SPHCC: Shanghai Public Health Clinical Center

UK: United Kingdom

USA: United States of America

WHO: World Health Organization

Journal Pre-proof

References

- Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. (2020). Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*, 323, 1406-1407.
- Chen F, Chen W, Chen J, Xu D, Xie W, Wang X, Xie Y. (2020). Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. *Ann Hepatol*, 21, 100267.
- Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. (2020). Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect*, 80, e1-e6.
- Chen L, Cai J, Lin Q, Xiang B, Ren T. (2020). Imported COVID-19 cases pose new challenges for China. *J Infect*, 80, e43-e44.
- Feng Y, Ling Y, Bai T et al. (2020). COVID-19 with Different Severity: A Multi-center Study of Clinical Features. *Am J Resp Crit Care*, 201, 1380-1388.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, 382, 1708-1720.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment

- Expert Group for Covid-19. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, 382, 1708-1720.
- Haehner A, Draef J, Draeger S, de With K, Hummel T. (2020). Predictive value of sudden olfactory loss in the diagnosis of COVID-19. medRxiv.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 395, 497-506.
- Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. (2020). Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. *Hepatology*, 72, 1169-1176.
- Jasti M, Nalleballe K, Dandu V, Onteddu S. (2020). A review of pathophysiology and neuropsychiatric manifestations of COVID-19. *J Neurol*, 1-6.
- Jie-Ming Q, Chen W, Bin C. (2020). Guidance for the management of adult patients with coronavirus disease 2019. *Chin Med J*, E030-E030.
- Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, Peng L, Cao H, Dai X, Liu J, Li X, Zhu J, Xu W, Chen D, Gao Z, He JR, Lin BL. (2020). A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. *Travel Med Infect Dis*, 101664.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B,

- Leung GM, Feng Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*, 382, 1199-1207.
- Liu X, Li X, Sun T, Qin H, Zhou Y, Zou C, Cao J, Zhang H. (2020). East-West differences in clinical manifestations of COVID-19 patients: A systematic literature review and meta-analysis. *J Med Virol*, 93, 2683-2693.
- Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, Wang L, Zhang L, Li QH, Zhao L, He Y, Gu XL, Ji XB, Li L, Jie ZJ, Li Q, Li XY, Lu HZ, Zhang WH, Song YL, Qu JM, Xu JF; Shanghai Clinical Treatment Experts Group for COVID-19. (2020). Association Between Ages and Clinical Characteristics and Outcomes of Coronavirus Disease 2019. *Eur Respir J*, 2001112.
- Livingston E, Bucher K. (2020). Coronavirus Disease 2019 (COVID-19) in Italy. *JAMA*, 323, 1335.
- Lu H, Ai J, Shen Y et al. (2020). A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. medRxiv, 2020.02.19.20025031.
- Mizumoto K, Kagaya K, Zarebski A, Chowell G. (2020). Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*, 25(10).
- Moein ST, Hashemian S, Mansourafshar BKhorram-Tousi A, Tabarsi P, Doty RL. (2020). Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*, 10(8):944-950.
- Oran DP, Topol EJ. (2020). Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. *Ann Intern Med*, 173, 362-367.

- Patel A, Charani E, Ariyanayagam D, Abdulaal A, Denny SJ, Mughal N, Moore LSP. (2020). New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. *Clin Microbiol Infect.*
- Qiu C, Cui C, Hautefort C, Haehner A, Zhao J, Yao Q, Zeng H, Nisenbaum EJ, Liu L, Zhao Y, Zhang D, Levine CG, Cejas I, Dai Q, Zeng M, Herman P, Jourdain C, de With K, Draf J, Chen B, Jayaweera DT, Denney JC 3rd, Casiano R, Yu H, Eshraghi AA, Hummel T, Liu X, Shu Y, Lu H. (2020). Olfactory and Gustatory Dysfunction as An Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. medRxiv.
- Saviano A, Wrensch F, Ghany MG, Baumert TF. (2020). Liver disease and COVID-19: from Pathogenesis to Clinical Care. *Hepatology*, 74, 1088-1100.
- The L. (2020). Sustaining containment of COVID-19 in China. *Lancet*, 395, 1230.
- Weiss P, Murdoch DR. (2020). Clinical course and mortality risk of severe COVID-19. *Lancet*, 395, 1014-1015.
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard.
- Wu Z, McGoogan JM. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*, 323, 1239-1242.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 395, 1054-1062.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F,

Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*, 382, 727-733.

Journal Pre-proof

Figure Legends

Figure 1. Screening strategy for native COVID-19 cases in Shanghai (Jan–Feb 2020)

Figure 2. Screening strategy for imported COVID-19 cases in Shanghai (Mar–April 2020)

Journal Pre-proof

Table 1. The demographics and baseline characteristics of COVID-19 imported cases from different countries outside of China, as compared to native cases in China.

| | Imported COVID-19 cases | | | | | P1 | Native Shanghai cohort | | National native cohort | |
|------------------------------|-------------------------|---------------|-----------------|---------------|----------------|-------------------|------------------------|-----------------|------------------------|-----------------|
| | US | Russia | UK | Other | Total | | P2 | | P3 | |
| Number | 34 | 86 | 76 | 51 | 247 | | 265 | | 1099 | |
| Female sex | 18 (52.9%) | 25 (29.1%) | 33 (43.4%) | 26 (51.0%) | 102 (41.3%) | 0.022 | | | 41.9% | 0.887 |
| Age (years), median (IQR) | 22 (19–34) | 35 (31–44) | 21 (19–24) | 32 (23–49) | 29 (21–40) | <.001 ① | | | 47 (35–58) | |
| 15–49 | 29 (85.3%) | 75 (87.2%) | 73 (96.1%) | 39 (76.5%) | 216 (87.4%) | 0.003 | | | 55.1% | <.001 |
| 50–64 | 3 (8.8%) | 11 (12.8%) | 3 (3.9%) | 11 (21.6%) | 28 (11.3%) | 0.003 | | | 28.9% | |
| ≥65 | 2 (5.9%) | 0 (0.0%) | 0 (0.0%) | 1 (2.0%) | 3 (1.2%) | 0.003 | | | 15.1% | |
| Smoking history | 1 (2.9%) | 20 (23.3%) | 4 (5.3%) | 2 (3.9%) | 27 (10.9%) | 0.001 ② | | | 12.6% | 0.395 |
| Current smoker | 0 (0.0%) | 1 (1.2%) | 0 (0.0%) | 1 (2.0%) | 2 (0.8%) | 0.001 | | | 1.9% | 0.395 |
| Former smoker | 0.1 (0.1–0.1) | 7.5 (5–15) | 2.35 (0.7–.) | 20 (20–20) | 7 (4–15) | 0.009 | | | | |
| Smoking history pack*years | 3 (8.8%) | 10 (11.6%) | 2 (2.6%) | 0 (0.0%) | 15 (6.1%) | 0.013 | | | | |
| Alcohol drinker | 3 (8.8%) | 10 (11.6%) | 2 (2.6%) | 0 (0.0%) | 15 (6.1%) | 0.013 | | | | |
| Coexisting disorders | | | | | | | | | | |
| Any | 13 (38.2%) | 29 (33.7%) | 10 (13.2%) | 15 (29.4%) | 67 (27.1%) | 0.005 ③ | | | 23.7% | 0.286 |
| Asthma | 0 (0.0%) | 2 (2.3%) | 1 (1.3%) | 2 (3.9%) | 5 (2.0%) | 0.754 | | | | |
| COPD | 0 | 0 | 0 | 0 | 0 | NA | 1.5% | | 1.1% | |
| Allergic rhinitis | 3 (8.8%) | 7 (8.1%) | 0 (0.0%) | 2 (3.9%) | 12 (4.9%) | 0.025 | | | | |
| Hepatitis B infection | 0 (0.0%) | 4 (4.7%) | 2 (2.6%) | 2 (3.9%) | 8 (3.2%) | 0.764 | 0.4% | 0.017 | 2.1% | 0.344 |
| Hypertension | 2 (5.9%) | 7 (8.1%) | 0 (0.0%) | 4 (7.8%) | 13 (5.3%) | 0.032 | 19.6% | <.001 | 15.0% | <.001 |
| Coronary heart disease | 0 | 0 | 0 | 0 | 0 | NA | 5.3% | <.001 | 2.5% | 0.009 |
| Other cardiovascular disease | 1 (2.9%) | 1 (1.2%) | 0 (0.0%) | 1 (2.0%) | 3 (1.2%) | 0.5 | | | | |
| Cerebrovascular disease | 0 | 0 | 0 | 0 | 0 | NA | 0.8% | | 1.4% | |
| Diabetes | 2 (5.9%) | 6 (7.0%) | 0 (0.0%) | 3 (5.9%) | 11 (4.5%) | 0.062 | 7.9% | 0.143 | 7.4% | 0.124 |

| | | | | | | | | | |
|-----------------------|--------|--------|--------|--------|--------|--------------|------|------|-------|
| Hyperlipidemia | 0 | 0 | 0 | 0 | 0 | NA | 1.5% | | |
| Chronic renal disease | 0 | 0 | 0 | 0 | 0 | NA | 1.9% | 0.7% | |
| Immunodeficiency | 2 | 0 | 0 | 0 | 2 | | | | |
| | (5.9%) | (0.0%) | (0.0%) | (0.0%) | (0.8%) | 0.018 | | 0.2% | 0.156 |
| Autoimmune diseases | 0 | 0 | 2 | 0 | 2 | | | | |
| | (0.0%) | (0.0%) | (2.6%) | (0.0%) | (0.8%) | 0.296 | 0.8% | 1 | |
| Tumor | 0 | 0 | 0 | 0 | 0 | NA | 2.3% | 0.9% | |

P1, P value of differences among different countries. P2, P value of differences between Shanghai native cases and imported cases. P3, P value of differences between national native cases and imported cases. T max: the maximum body temperature.

In pairwise comparison, ① values of cases originating from Russia were significantly higher than those of cases originating from the US and UK; values of cases from other countries were higher than those of cases from the UK. ② Values of cases from Russia were significantly higher than those of cases from the UK and other countries, $P = 0.001$ and 0.004 , respectively. ③ Values of cases originating from the US and Russia were significantly higher than those of cases originating from the UK, $P = 0.005$ and $P = 0.003$, respectively.

Data are presented as n (%), unless otherwise specified.

Table 2. The clinical manifestations of COVID-19 imported cases from different countries outside of China, as compared to native cases in China.

| | Imported COVID-19 cases | | | | | P1 | Native Shanghai cohort | | National native cohort | |
|---|-------------------------|---------------|---------------|---------------|----------------|--------|------------------------|-------|------------------------|-------|
| | US | Russia | UK | Other | Total | | P2 | | P3 | |
| Number | 34 | 86 | 76 | 51 | 247 | | 265 | | 1099 | |
| Interval between symptom onset and admission (days) | 3 (2–7) | 5 (2.25–7) | 4 (2–8.25) | 5 (2–10) | 4 (2–8) | 0.643 | | | | |
| Asymptomatic | 7 (20.6%) | 6 (7.0%) | 10 (13.2%) | 6 (11.8%) | 29 (11.7%) | 0.189 | | | | |
| Fever during disease course (%) | 15 (44.1%) | 37 (43.0%) | 37 (48.7%) | 20 (39.2%) | 109 (44.1%) | 0.766 | 90.9% | <.001 | 88.7% | <.001 |
| T max <37.5°C | 20 (58.8%) | 52 (60.5%) | 42 (55.3%) | 33 (64.7%) | 147 (59.5%) | 0.915 | | | 9.9% | <.001 |
| 37.5–38.0°C | 9 (26.5%) | 23 (26.7%) | 27 (35.5%) | 11 (21.6%) | 70 (28.3%) | | | | 30.9% | |
| 38.1–39.0°C | 5 (14.7%) | 9 (10.5%) | 7 (9.2%) | 7 (13.7%) | 28 (11.3%) | | | | 46.9% | |
| >39.0°C | 0 (0.0%) | 2 (2.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | | | | 12.3% | |
| Chills | 1 (2.9%) | 9 (10.5%) | 0 (0.0%) | 3 (5.9%) | 13 (5.3%) | 0.012① | | | 11.5% | 0.003 |
| Night sweats | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 1 (2.0%) | 2 (0.8%) | 0.644 | | | | |
| Dizziness | 0 (0.0%) | 2 (2.3%) | 1 (1.3%) | 0 (0.0%) | 3 (1.2%) | 0.866 | | | | |
| Headache | 2 (5.9%) | 12 (14.0%) | 5 (6.6%) | 10 (19.6%) | 29 (11.7%) | 0.097 | 9.8% | 0.569 | 13.6% | 0.469 |
| Sore throat | 4 (11.8%) | 9 (10.5%) | 5 (6.6%) | 2 (3.9%) | 20 (8.1%) | 0.419 | 4.5% | 0.143 | 13.9% | 0.012 |
| Itchy throat | 5 (14.7%) | 28 (32.6%) | 18 (23.7%) | 16 (31.4%) | 67 (27.1%) | 0.177 | | | | |
| Nasal congestion | 1 (2.9%) | 14 (16.3%) | 13 (17.1%) | 11 (21.6%) | 39 (15.8%) | 0.091 | | | 4.8% | <.001 |
| Rhinorrhea | 2 (5.9%) | 10 (11.6%) | 8 (10.5%) | 6 (11.8%) | 26 (10.5%) | 0.858 | 6.0% | 0.078 | | |
| Cough | 13 (38.2%) | 43 (50.0%) | 33 (43.4%) | 24 (47.1%) | 113 (45.7%) | 0.663 | 49.4% | 0.48 | 67.8% | <.001 |
| Sputum production | 7 (20.6%) | 22 (25.6%) | 16 (21.1%) | 12 (23.5%) | 57 (23.1%) | 0.914 | 23.0% | 1 | 33.7% | 0.001 |
| Hemoptysis | 0 (0.0%) | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) | 1 | | | 0.9% | 0.7 |

| | | | | | | | | | | |
|--|---------------|---------------|---------------|---------------|----------------|--------|-------|-------|-------|-------|
| Fatigue | 3 (8.8%) | 9 (10.5%) | 9 (11.8%) | 4 (7.8%) | 25 (10.1%) | 0.919 | 25.3% | <.001 | 38.1% | <.001 |
| Myalgia or arthralgia | 2 (5.9%) | 10 (11.6%) | 5 (6.6%) | 1 (2.0%) | 18 (7.3%) | 0.206 | 8.7% | 0.626 | 14.9% | 0.001 |
| Chest pain | 0 (0.0%) | 3 (3.5%) | 0 (0.0%) | 0 (0.0%) | 3 (1.2%) | 0.227 | 2.3% | 0.506 | | |
| Dyspnea or chest tightness | 0 (0.0%) | 14 (16.3%) | 2 (2.6%) | 6 (11.8%) | 22 (8.9%) | 0.003① | 6.4% | 0.322 | 18.7% | <.001 |
| Ageusia or anosmia | 5 (14.7%) | 5 (5.8%) | 10 (13.2%) | 4 (7.8%) | 24 (9.7%) | 0.272 | | | | |
| Nausea or vomiting | 0 (0.0%) | 4 (4.7%) | 2 (2.6%) | 0 (0.0%) | 6 (2.4%) | 0.415 | 2.3% | 1 | 5.0% | 0.09 |
| Abdominal pain | 0 (0.0%) | 2 (2.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | 0.515 | | | | |
| Abdominal distention | 0 (0.0%) | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) | 1 | | | | |
| Diarrhea | 3 (8.8%) | 15 (17.4%) | 4 (5.3%) | 4 (7.8%) | 26 (10.5%) | 0.081 | 6.4% | 0.084 | 3.8% | <.001 |
| Highest severity during disease course | | | | | | 0.004② | | <.001 | | |
| Mild | 10 (29.4%) | 18 (21.2%) | 35 (46.1%) | 21 (41.2%) | 84 (34.1%) | | 1.9% | | | |
| Moderate | 23 (67.6%) | 64 (75.3%) | 41 (53.9%) | 28 (54.9%) | 156 (63.4%) | | 89.8% | | | |
| Severe | 0 (0.0%) | 3 (3.5%) | 0 (0.0%) | 2 (3.9%) | 5 (2.0%) | | 3.8% | | | |
| Critical | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) | | 4.5% | | | |
| Diagnosed pneumonia | 24 (70.6%) | 67 (77.9%) | 41 (53.9%) | 30 (58.8%) | 162 (65.6%) | 0.006③ | | | 91.1% | <.001 |
| Severe-critical | 1 (2.9%) | 3 (3.5%) | 0 (0.0%) | 2 (3.9%) | 6 (2.4%) | 0.254 | 8.3% | 0.003 | 15.7% | <.001 |
| Hospital LOS (days) | 16 (13–20) | 14 (12–19) | 16 (12–21) | 14 (12–19) | 15 (12–20) | 0.099 | | | | |

P1, P value of differences among different countries. P2, P value of differences between Shanghai native cases and imported cases. P3, P value of differences between national native cases and imported cases. T max: the maximum body temperature.

In pairwise comparison, ① Values of cases originating from Russia were significantly higher than those of cases originating from the UK, $P = 0.004$. ② Values of cases originating from Russia were significantly higher than those of cases originating from the UK, $P < 0.001$. ③ Values of cases originating from Russia were significantly higher than those of cases originating from the UK, $P = 0.002$.

Data are presented as n (%), unless otherwise specified.

Table 3. Laboratory and radiographic findings of COVID-19 cases imported from different countries at admission, as compared with native Chinese cases

| | Import COVID-19 cohort | | | | | Native Shanghai cohort | | Native national cohort |
|--|------------------------|---------------|---------------|---------------|----------------|------------------------|----|--------------------------|
| | U.S.A. | Russia | U.K. | Other | Total | P1 | P2 | P3 |
| White blood cell count <4000/mm ³ | 6 (17.6%) | 10 (11.6%) | 12 (15.8%) | 8 (15.7%) | 36 (14.6%) | 0.944 | | 33.7% <.001 |
| White blood cell count >10,000/mm ³ | 1 (2.9%) | 2 (2.3%) | 3 (3.9%) | 1 (2.0%) | 7 (2.8%) | 0.944 | | 5.9% |
| Platelet count <150,000/mm ³ | 4 (11.8%) | 10 (11.6%) | 3 (3.9%) | 5 (9.8%) | 22 (8.9%) | 0.284 | | 36.2% <.001 |
| Platelet count >400,000/mm ³ | 1 (2.9%) | 2 (2.3%) | 0 (0.0%) | 1 (2.0%) | 4 (1.6%) | 0.284 | | |
| Neutrophil % <50% | 11 (32.4%) | 12 (14.0%) | 13 (17.1%) | 6 (11.8%) | 42 (17.0%) | 0.304 | | |
| Neutrophil % >70% | 5 (14.7%) | 13 (15.1%) | 11 (14.5%) | 10 (19.6%) | 39 (15.8%) | 0.304 | | |
| Lymphocyte count <1500/mm ³ | 11 (32.4%) | 40 (46.5%) | 22 (28.9%) | 24 (47.1%) | 97 (39.3%) | 0.06 | | 83.2% <.001 |
| C-reactive protein ≥10 mg/L | 1 (2.9%) | 11 (12.8%) | 3 (3.9%) | 3 (5.9%) | 18 (7.3%) | 0.129 | | 60.7% <.001 |
| Alanine aminotransferase >40 U/L | 4 (11.8%) | 17 (19.8%) | 9 (11.8%) | 7 (13.7%) | 37 (15.0%) | 0.526 | | 21.3% 0.034 |
| Aspartate aminotransferase >40 U/L | 1 (2.9%) | 4 (4.7%) | 1 (1.3%) | 3 (5.9%) | 9 (3.6%) | 0.477 | | 22.2% <.001 |
| Total bilirubin >17.1 μmol/L | 2 (5.9%) | 11 (12.8%) | 7 (9.2%) | 2 (3.9%) | 22 (8.9%) | 0.348 | | 10.5% 0.541 |
| Creatinine ≥133 μmol/L | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | NA | | 1.6% 0.045 |
| Creatine kinase ≥200 U/L | 1 (2.9%) | 8 (9.3%) | 6 (8.1%) | 2 (3.9%) | 17 (6.9%) | 0.543 | | 13.7% 0.005 |
| Lactate dehydrogenase ≥250 U/L | 2 (5.9%) | 9 (10.5%) | 4 (5.3%) | 6 (11.8%) | 21 (8.5%) | 0.489 | | 41.0% <.001 |
| D-dimer ≥0.5 mg/L | 5 (14.7%) | 14 (16.5%) | 11 (14.5%) | 10 (19.6%) | 40 (16.3%) | 0.883 | | 46.4% <.001 |
| Albumin <40 g/L | 1 (2.9%) | 15 (17.4%) | 3 (3.9%) | 4 (7.8%) | 23 (9.3%) | 0.015 | | |
| Venous lactate >2.2 mmol/L | 9 (26.5%) | 54 (62.8%) | 25 (34.2%) | 21 (42.0%) | 109 (44.9%) | 0.001 ① | | |
| Arterial lactate ≤1.5 mmol/L | 22 (71.0%) | 29 (34.5%) | 48 (69.6%) | 40 (80.0%) | 139 (59.4%) | 0 | | |
| Arterial lactate 1.5-2 mmol/L | 4 (12.9%) | 17 (20.2%) | 11 (15.9%) | 6 (12.0%) | 38 (16.2%) | 0 | | |
| Arterial lactate 2-4 | 5 | 32 | 10 | 4 | 51 | 0 | | |

| | | | | | | | | |
|----------------------------------|---------|---------|---------|---------|---------|----------------|-------|-----------------|
| mmol/L | (16.1%) | (38.1%) | (14.5%) | (8.0%) | (21.8%) | | | |
| Arterial lactate >4 mmol/L | 0 | 6 | 0 | 0 | 6 | | | |
| SARS-COV-2 antibody | (0.0%) | (7.1%) | (0.0%) | (0.0%) | (2.6%) | 0 | | |
| Positive | 12 | 43 | 43 | 29 | 127 | | | |
| | (35.3%) | (50.0%) | (56.6%) | (56.9%) | (51.4%) | 0.24 | | |
| Weakly positive | 3 | 7 | 2 | 3 | 15 | | | |
| | (8.8%) | (8.1%) | (2.6%) | (5.9%) | (6.1%) | | | |
| Negative | 19 | 36 | 31 | 19 | 105 | | | |
| | (55.9%) | (41.9%) | (40.8%) | (37.3%) | (42.5%) | | | |
| Abnormalities on chest CT | 17 | 59 | 34 | 30 | 140 | | | |
| | (50.0%) | (68.6%) | (44.7%) | (58.8%) | (56.7%) | 0.017 ② | 86.2% | |
| Unilateral involvement | 8 | 16 | 18 | 14 | 56 | | | |
| | (23.5%) | (18.6%) | (23.7%) | (27.5%) | (22.7%) | 0.001 ① | 19.2% | <.001 |
| Bilateral involvement | 9 | 43 | 16 | 16 | 84 | | | |
| | (26.5%) | (50.0%) | (21.1%) | (31.4%) | (34.0%) | | 77.4% | |
| Number of lung lobes involved | | | | | | | | |
| 0 | 17 | 27 | 42 | 21 | 107 | | | |
| | (53.1%) | (32.9%) | (56.8%) | (42.9%) | (45.1%) | 0.000 ③ | | |
| 1 | 6 | 14 | 17 | 14 | 51 | | | |
| | (18.8%) | (17.1%) | (23.0%) | (28.6%) | (21.5%) | | | |
| 2 | 6 | 12 | 7 | 6 | 31 | | | |
| | (18.8%) | (14.6%) | (9.5%) | (12.2%) | (13.1%) | | | |
| 3 | 1 | 8 | 5 | 3 | 17 | | | |
| | (3.1%) | (9.8%) | (6.8%) | (6.1%) | (7.2%) | | | |
| 4 | 1 | 7 | 1 | 2 | 11 | | | |
| | (3.1%) | (8.5%) | (1.4%) | (4.1%) | (4.6%) | | | |
| 5 | 1 | 14 | 2 | 3 | 20 | | | |
| | (3.1%) | (17.1%) | (2.7%) | (6.1%) | (8.4%) | | | |
| Ground-glass opacity | 14 | 37 | 21 | 22 | 94 | | | |
| | (41.2%) | (43.0%) | (27.6%) | (43.1%) | (38.1%) | 0.155 | 56.4% | <.001 |
| Interlobular septal thickening | 5 | 25 | 14 | 13 | 57 | | | |
| | (14.7%) | (29.1%) | (18.4%) | (25.5%) | (23.1%) | 0.246 | | |
| Patchy effusion or consolidation | 5 | 31 | 16 | 12 | 64 | | | |
| | (14.7%) | (36.0%) | (21.1%) | (23.5%) | (25.9%) | 0.054 | | |

P1, P value of the difference among different countries. P2, P value of differences between the native Shanghai cases and the imported cases. P3, P value of differences between the national native cases and imported cases. In pairwise comparisons, ① the values of cases originating from Russia were significantly higher than those of cases originating from the UK, P = 0.001. ② The values of cases originating from Russia were significantly higher than those of cases originating from the UK, P = 0.003. ③ The values of cases originating from Russia were significantly higher than those of cases originating from the UK, P < 0.001.

Data are presented as n (%).

Table 4. The demographics and baseline characteristics of imported COVID-19 cases with different severity, compared to the native cases

| | Imported cases | | | | | Native cases | | |
|------------------------------|----------------|----------------|---------------|---------------|----------------|-----------------|----------------|-------|
| | Mild | Moderate | Severe | Critical | Total | P1 | Moderate | P2 |
| Number | 84 | 156 | 5 | 1 | 246 | | | |
| Female sex | 35 (41.7%) | 65 (41.7%) | 1 (20.0%) | 0 (0.0%) | 101 (41.1%) | 0.7 | 162 (46.0%) | 0.385 |
| Age (years), median (IQR) | 22 (19–31) | 32 (22–44) | 49 (34–52) | 75 (75–75) | | <.001 | | |
| 15–49 | 81 (96.4%) | 131 (84.0%) | 3 (60.0%) | 0 (0.0%) | 215 (87.4%) | <.001 | | |
| 50–64 | 3 (3.6%) | 23 (14.7%) | 2 (40.0%) | 0 (0.0%) | 28 (11.4%) | | | |
| ≥65 | 0 (0.0%) | 2 (1.3%) | 0 (0.0%) | 1 (100.0%) | 3 (1.2%) | | | |
| Smoking history | 11 | 15 | 1 | 0 | 27 | | 27 | |
| Current | (13.1%) | (9.6%) | (20.0%) | (0.0%) | (11.0%) | 0.525 | (8.1%) | 0.314 |
| Former | 0 (0.0%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | 0.525 | | |
| Alcohol drinker | 4 (4.8%) | 11 (7.1%) | 0 (0.0%) | 0 (0.0%) | 15 (6.1%) | 0.727 | 20 (6.0%) | 0.692 |
| Coexisting disorder | | | | | | | | |
| Any | 13 (15.5%) | 49 (31.4%) | 4 (80.0%) | 1 (100.0%) | 67 (27.2%) | <.001 | | |
| Asthma | 1 (1.2%) | 4 (2.6%) | 0 (0.0%) | 0 (0.0%) | 5 (2.0%) | 0.656 | | |
| Allergic rhinitis | 6 (7.1%) | 6 (3.8%) | 0 (0.0%) | 0 (0.0%) | 12 (4.9%) | 0.248 | | |
| Hepatitis B infection | 2 (2.4%) | 6 (3.8%) | 0 (0.0%) | 0 (0.0%) | 8 (3.3%) | 0.721 | | |
| Hypertension | 1 (1.2%) | 9 (5.8%) | 2 (40.0%) | 1 (100.0%) | 13 (5.3%) | 0.002 | | |
| Other cardiovascular disease | 0 (0.0%) | 3 (1.9%) | 0 (0.0%) | 0 (0.0%) | 3 (1.2%) | 0.551 | | |
| Diabetes | 0 (0.0%) | 7 (4.5%) | 3 (60.0%) | 1 (100.0%) | 11 (4.5%) | <.001 | | |
| Immunodeficiency | 0 (0.0%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | 0.551 | | |
| Autoimmune diseases | 1 (1.2%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | 0.985 | | |

P1: *P* value of the difference among different severities. P2: *P* value of the difference between native and imported cases. T max: the maximum body temperature. Data are presented as n (%), unless otherwise specified.

Supplementary Table 1. The clinical manifestations of imported COVID-19 cases with different severity, compared to the native cases

| | Imported cases | | | | | Native cases | | |
|---|-----------------|-----------------|-----------------|---------------------|----------------|--------------|----------------|-------|
| | Mild | Moderate | Severe | Critical | Total | P1 | Moderate | P2 |
| Interval between symptom onset and admission (days) | 4 (2–7) | 4 (2–8) | 7 (3.5–13) | 1 (1–1) | 4 (2–8) | 0.476 | | |
| Asymptomatic | 13 (15.5%) | 16 (10.3%) | 0 (0.0%) | 0 (0.0%) | 29 (11.8%) | 0.175 | | |
| Fever during disease course (%) | 35 (41.7%) | 69 (44.2%) | 3 (60.0%) | 1 (100.0%) | 108 (43.9%) | 0.48 | 277 (82.2%) | <.001 |
| Maximum temperature | 37 (37–37.8) | 37 (37–37.8) | 38 (37–38.6) | 37.7 (37.7–37.7) | | 0.288 | | |
| T max <37.5°C | 52 (61.9%) | 93 (59.6%) | 2 (40.0%) | 0 (0.0%) | 147 (59.8%) | 0.204 | | |
| 37.5–38.0°C | 27 (32.1%) | 40 (25.6%) | 1 (20.0%) | 1 (100.0%) | 69 (28.0%) | | | |
| 38.1–39.0°C | 5 (6.0%) | 21 (13.5%) | 2 (40.0%) | 0 (0.0%) | 28 (11.4%) | | | |
| >39.0°C | 0 (0.0%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | | | |
| Chills | 4 (4.8%) | 8 (5.1%) | 1 (20.0%) | 0 (0.0%) | 13 (5.3%) | 0.618 | 17 (5.7%) | 1 |
| Night sweats | 0 (0.0%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.8%) | 0.55 | | |
| Dizziness | 1 (1.2%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 3 (1.2%) | 1 | | |
| Headache | 9 (10.7%) | 18 (11.5%) | 1 (20.0%) | 0 (0.0%) | 28 (11.4%) | 0.826 | | |
| Sore throat | 7 (8.3%) | 12 (7.7%) | 1 (20.0%) | 0 (0.0%) | 20 (8.1%) | 0.991 | 26 (7.9%) | 1 |
| Itchy throat | 18 (21.4%) | 49 (31.4%) | 0 (0.0%) | 0 (0.0%) | 67 (27.2%) | 0.286 | | |
| Nasal congestion | 12 (14.3%) | 27 (17.3%) | 0 (0.0%) | 0 (0.0%) | 39 (15.9%) | 0.802 | | |
| Rhinorrhea | 8 (9.5%) | 18 (11.5%) | 0 (0.0%) | 0 (0.0%) | 26 (10.6%) | 0.924 | | |
| Cough | 24 (28.6%) | 84 (53.8%) | 4 (80.0%) | 0 (0.0%) | 112 (45.5%) | <.001 | 220 (65.5%) | 0.017 |
| Sputum production | 11 (13.1%) | 42 (26.9%) | 3 (60.0%) | 0 (0.0%) | 56 (22.8%) | 0.004 | 100 (29.8%) | 0.593 |
| Hemoptysis | 0 (0.0%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) | 1 | 2 (0.6%) | 1 |

| | | | | | | | | |
|----------------------------|---------|---------|---------|--------|---------|-------|---------|--------------|
| | 9 | 16 | 0 | 0 | 25 | | | |
| | (10.7%) | (10.3%) | (0.0%) | (0.0%) | (10.2%) | 0.756 | | |
| Fatigue | | | | | | | | |
| | 7 | 10 | 0 | 0 | 17 | | 38 | |
| | (8.3%) | (6.4%) | (0.0%) | (0.0%) | (6.9%) | 0.561 | (11.4%) | 0.103 |
| Myalgia or arthralgia | | | | | | | | |
| | 1 | 2 | 0 | 0 | 3 | | 13 | |
| | (1.2%) | (1.3%) | (0.0%) | (0.0%) | (1.2%) | 1 | (3.9%) | 0.161 |
| Chest pain | | | | | | | | |
| | 7 | 13 | 2 | 0 | 22 | | 50 | |
| | (8.3%) | (8.3%) | (40.0%) | (0.0%) | (8.9%) | 0.522 | (14.9%) | 0.043 |
| Dyspnea or chest tightness | | | | | | | | |
| | 14 | 10 | 0 | 0 | 24 | | | |
| | (16.7%) | (6.4%) | (0.0%) | (0.0%) | (9.8%) | 0.009 | | |
| Ageusia or anosmia | | | | | | | | |
| | 2 | 4 | 0 | 0 | 6 | | | |
| | (2.4%) | (2.6%) | (0.0%) | (0.0%) | (2.4%) | 1 | | |
| Nausea or vomiting | | | | | | | | |
| | 1 | 1 | 0 | 0 | 2 | | | |
| | (1.2%) | (0.6%) | (0.0%) | (0.0%) | (0.8%) | 0.983 | | |
| Abdominal pain | | | | | | | | |
| | 8 | 18 | 0 | 0 | 26 | | | |
| | (9.5%) | (11.5%) | (0.0%) | (0.0%) | (10.6%) | 0.92 | | |
| Diarrhea | | | | | | | | |
| | 15 | 15 | 24 | | 15 | | | |
| | (12-20) | (12-20) | (17-31) | | (12-20) | | | |
| Hospital LOS (days) | | | | | | | | |

P1: *P* value of the difference among different severities. P2: *P* value of the difference between native and imported cases. T max: the maximum body temperature.

Data are presented as n (%), unless otherwise specified.

Supplementary Table 2. Laboratory and radiographic findings of the imported COVID-19 cases with different severities, compared with native cases.

| | Imported COVID-19 cases | | | | | Native cases | | |
|--|-------------------------|---------------|---------------|---------------|----------------|-----------------|---------------|-----------------|
| | Mild | Moderate | Severe | Critical | Total | P1 | Moderate | P2 |
| White-cell count <4000/mm ³ | 7 (8.3%) | 26 (16.7%) | 3 (60.0%) | 0 (0.0%) | 36 (14.6%) | 0.026 | 67 (19.1%) | 0.36 |
| White-cell count >10,000/mm ³ | 1 (1.2%) | 6 (3.8%) | 0 (0.0%) | 0 (0.0%) | 7 (2.8%) | | 23 (6.6%) | 0.36 |
| Platelet count <150,000/mm ³ | 5 (6.0%) | 17 (10.9%) | 0 (0.0%) | 0 (0.0%) | 22 (8.9%) | 0.705 | | |
| Platelet count >400,000/mm ³ | 1 (1.2%) | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 3 (1.2%) | | | |
| Neutrophil % <50% | 17 (20.2%) | 25 (16.0%) | 0 (0.0%) | 0 (0.0%) | 42 (17.1%) | 0.429 | | |
| Neutrophil % >70% | 13 (15.5%) | 22 (14.1%) | 3 (60.0%) | 1 (100.0%) | 39 (15.9%) | | | |
| Lymphocyte count <1500/mm ³ | 18 (21.4%) | 72 (46.2%) | 5 (100.0%) | 1 (100.0%) | 96 (39.0%) | <.001 | | |
| C-reactive protein ≥10 mg/L | 2 (2.4%) | 12 (7.7%) | 4 (80.0%) | 0 (0.0%) | 18 (7.3%) | 0.001 | 169 (55.%) | <.001 |
| Alanine aminotransferase >40 U/L | 6 (7.1%) | 30 (19.2%) | 1 (20.0%) | 0 (0.0%) | 37 (15.0%) | 0.018 | | |
| Aspartate aminotransferase >40 U/L | 0 (0.0%) | 7 (4.5%) | 2 (40.0%) | 0 (0.0%) | 9 (3.7%) | 0.002 | | |
| Lactate dehydrogenase ≥250 U/L | 0 (0.0%) | 18 (11.5%) | 3 (60.0%) | 0 (0.0%) | 21 (8.5%) | <.001 | | |
| Total bilirubin >17.1 µmol/L | 8 (9.5%) | 14 (9.0%) | 0 (0.0%) | 0 (0.0%) | 22 (8.9%) | 0.75 | | |
| Albumin <40 g/L | 1 (1.2%) | 19 (12.2%) | 3 (60.0%) | 0 (0.0%) | 23 (9.3%) | <.001 | | |
| Creatine kinase ≥200 U/L | 3 (3.7%) | 13 (8.3%) | 0 (0.0%) | 1 (100.0%) | 17 (7.0%) | 0.107 | | |
| Venous lactate >2.2 mmol/L | 39 (48.1%) | 69 (44.2%) | 0 (0.0%) | 0 (0.0%) | 108 (44.6%) | 0.238 | | |
| Arterial lactate ≤1.5 mmol/L | 48 (62.3%) | 87 (58.0%) | 3 (60.0%) | 1 (100.0%) | 139 (59.7%) | 0.436 | | |
| Arterial lactate 1.5–2 mmol/L | 14 (18.2%) | 23 (15.3%) | 1 (20.0%) | 0 (0.0%) | 38 (16.3%) | | | |
| Arterial lactate 2–4 mmol/L | 15 (19.5%) | 34 (22.7%) | 1 (20.0%) | 0 (0.0%) | 50 (21.5%) | | | |
| Arterial lactate >4 mmol/L | 0 (0.0%) | 6 (4.0%) | 0 (0.0%) | 0 (0.0%) | 6 (2.6%) | | | |

| | | | | | | |
|----------------------------------|---------|---------|----------|----------|---------|-----------------|
| | 9 | 27 | 3 | 0 | 39 | |
| D-dimer ≥ 0.5 mg/L | (10.7%) | (17.4%) | (60.0%) | (0.0%) | (15.9%) | 0.04 |
| SARS-COV-2 antibody | 45 | 79 | 2 | 0 | 126 | |
| Positive | (53.6%) | (50.6%) | (40.0%) | (0.0%) | (51.2%) | 0.776 |
| Weakly positive | 2 | 12 | 1 | 0 | 15 | |
| | (2.4%) | (7.7%) | (20.0%) | (0.0%) | (6.1%) | |
| Negative | 37 | 65 | 2 | 1 | 105 | |
| | (44.0%) | (41.7%) | (40.0%) | (100.0%) | (42.7%) | |
| Abnormalities on chest CT | 5 | 129 | 5 | 1 | 140 | |
| | (6.0%) | (82.7%) | (100.0%) | (100.0%) | (56.9%) | <.001 |
| Unilateral involvement | 3 | 52 | 0 | 1 | 56 | |
| | (3.6%) | (33.3%) | (0.0%) | (100.0%) | (22.8%) | |
| Bilateral involvement | 2 | 77 | 5 | 0 | 84 | |
| | (2.4%) | (49.4%) | (100.0%) | (0.0%) | (34.1%) | 0.097 |
| Number of lung lobes involved | | | | | | |
| 0 | 79 | 27 | 0 | 0 | 106 | |
| | (94.0%) | (18.4%) | (0.0%) | (0.0%) | (44.9%) | |
| 1 | 3 | 47 | 0 | 1 | 51 | |
| | (3.6%) | (32.0%) | (0.0%) | (100.0%) | (21.6%) | 0.049 |
| 2 | 0 | 30 | 1 | 0 | 31 | |
| | (0.0%) | (20.4%) | (25.0%) | (0.0%) | (13.1%) | |
| 3 | 2 | 15 | 0 | 0 | 17 | |
| | (2.4%) | (10.2%) | (0.0%) | (0.0%) | (7.2%) | |
| 4 | 0 | 11 | 0 | 0 | 11 | |
| | (0.0%) | (7.5%) | (0.0%) | (0.0%) | (4.7%) | |
| 5 | 0 | 17 | 3 | 0 | 20 | |
| | (0.0%) | (11.6%) | (75.0%) | (0.0%) | (8.5%) | |
| Ground-glass opacity | 3 | 87 | 3 | 1 | 94 | |
| | (3.6%) | (55.8%) | (60.0%) | (100.0%) | (38.2%) | 0.593 |
| Interlobular septal thickening | 1 | 53 | 3 | 0 | 57 | |
| | (1.2%) | (34.0%) | (60.0%) | (0.0%) | (23.2%) | 0.431 |
| Patchy effusion or consolidation | 3 | 58 | 2 | 1 | 64 | |
| | (3.6%) | (37.2%) | (40.0%) | (100.0%) | (26.0%) | 0.517 |

P1: P value of the differences among imported cases of different severity. P2, P values of the differences between native and imported cases.

Data are presented as n (%).

Supplementary Table 3. Comparison of the clinical characteristics between asymptomatic and symptomatic imported cases

| Characteristic | Asymptomatic | Symptomatic | <i>P</i> value |
|--|--------------|-------------|----------------|
| Number | 29 | 218 | |
| Female | 12 (41.4%) | 90 (41.3%) | 1 |
| Age (years), median (IQR) | 23 (19-34) | 30 (21-41) | 0.082 |
| 15–49 | 28 (96.6%) | 188 (86.2%) | 0.139 |
| 50–64 | 1 (3.4%) | 27 (12.4%) | |
| ≥65 | 0 (0.0%) | 3 (1.4%) | |
| Smoking history | | | |
| Current smoker | 5 (17.2%) | 22 (10.1%) | 0.095 |
| Former smoker | 1 (3.4%) | 1 (0.5%) | |
| Alcohol drinker | 3 (10.3%) | 12 (5.5%) | 0.396 |
| Coexisting disorder | | | |
| Any | 5 (17.2%) | 62 (28.4%) | 0.268 |
| Asthma | 0 (0.0%) | 5 (2.3%) | 1 |
| Allergic rhinitis | 0 (0.0%) | 12 (5.5%) | 0.37 |
| Hepatitis B infection | 1 (3.4%) | 7 (3.2%) | 1 |
| Hypertension | 1 (3.4%) | 12 (5.5%) | 1 |
| Other cardiovascular disease | 0 (0.0%) | 3 (1.4%) | 1 |
| Diabetes | 0 (0.0%) | 11 (5.0%) | 0.371 |
| Immunodeficiency | 0 (0.0%) | 2 (0.9%) | 1 |
| Autoimmune diseases | 0 (0.0%) | 2 (0.9%) | 1 |
| Mild | 13 (44.8%) | 71 (32.7%) | 0.182 |
| Moderate | 16 (55.2%) | 140 (64.5%) | |
| Severe | 0 (0.0%) | 5 (2.3%) | |
| Critically | 0 (0.0%) | 1 (0.5%) | |
| Diagnosed pneumonia | 16 (55.2%) | 146 (67.0%) | 0.218 |
| Severe-critical | 0 (0.0%) | 6 (2.8%) | 1 |
| Hospital LOS (days) | 14 (10-18) | 15 (12-20) | 0.260 |
| White-cell count <4000/mm ³ | 4 (13.8%) | 32 (14.7%) | 1 |
| White-cell count >10,000/mm ³ | 0 (0.0%) | 7 (3.2%) | |
| Platelet count <150,000/mm ³ | 3 (10.3%) | 19 (8.7%) | 0.4 |
| Platelet count >400,000/mm ³ | 1 (3.4%) | 3 (1.4%) | |
| Neutrophil % <50% | 6 (20.7%) | 36 (16.5%) | 0.363 |
| Neutrophil % >70% | 2 (6.9%) | 37 (17.0%) | 0.363 |
| Lymphocyte count <1500/mm ³ | 7 (24.1%) | 90 (41.3%) | 0.104 |
| C-reactive protein ≥10 mg/L | 0 (0.0%) | 18 (8.3%) | 0.142 |
| Alanine aminotransferase >40 U/L | 4 (13.8%) | 33 (15.1%) | 1 |
| Aspartate aminotransferase >40 U/L | 1 (3.4%) | 8 (3.7%) | 1 |
| Lactate dehydrogenase ≥250 U/L | 2 (6.9%) | 19 (8.7%) | 1 |
| Total bilirubin >17.1 μmol/L | 1 (3.4%) | 21 (9.6%) | 0.486 |

| | | | |
|--|------------|-------------|--------------|
| Albumin <40g/L | 4 (13.8%) | 19 (8.7%) | 0.325 |
| Creatinine $\geq 133 \mu\text{mol/L}$ | 0 | 0 | |
| Creatine kinase $\geq 200 \text{ U/L}$ | 0 (0.0%) | 17 (7.9%) | 0.234 |
| Venous lactate >2.2 mmol/L | 11 (39.3%) | 98 (45.6%) | 0.552 |
| Arterial lactate $\leq 1.5 \text{ mmol/L}$ | 16 (64.0%) | 123 (58.9%) | |
| Arterial lactate 1.5-2 mmol/L | 2 (8.0%) | 36 (17.2%) | 0.876 |
| Arterial lactate 2-4 mmol/L | 6 (24.0%) | 45 (21.5%) | |
| Arterial lactate >4 mmol/L | 1 (4.0%) | 5 (2.4%) | |
| D-dimer $\geq 0.5 \text{ mg/L}$ | 2 (6.9%) | 38 (17.5%) | 0.186 |
| Antibody of SARS-COV-2 | | | |
| Positive | 10 (34.5%) | 95 (43.6%) | 0.172 |
| Weakly positive | 0 (0.0%) | 15 (6.9%) | |
| Negative | 19 (65.5%) | 108 (49.5%) | |
| Abnormalities on chest CT | 13 (44.8%) | 127 (58.3%) | 0.231 |
| Unilateral involvement | 8 (27.6%) | 48 (22.0%) | |
| Bilateral involvement | 5 (17.2%) | 79 (36.2%) | 0.042 |
| Number of lung lobes involved | | | |
| 1 | 8 (28.6%) | 43 (20.6%) | 0.018 |
| 2 | 3 (10.7%) | 28 (13.4%) | |
| 3 | 0 (0.0%) | 17 (8.1%) | |
| 4 | 1 (3.6%) | 10 (4.8%) | |
| 5 | 0 (0.0%) | 20 (9.6%) | |
| Ground-glass opacity | 5 (17.2%) | 89 (40.8%) | 0.014 |
| Interlobular septal thickening | 4 (13.8%) | 53 (24.3%) | 0.248 |
| Patchy effusion or consolidation | 8 (27.6%) | 56 (25.7%) | 0.824 |



